Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Gross Profit (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Gross Profit data on record, last reported at $763000.0 in Q4 2025.

  • For Q4 2025, Gross Profit fell 91.03% year-over-year to $763000.0; the TTM value through Dec 2025 reached $5.7 million, down 64.0%, while the annual FY2025 figure was $5.7 million, 63.99% down from the prior year.
  • Gross Profit reached $763000.0 in Q4 2025 per ACRS's latest filing, down from $2.8 million in the prior quarter.
  • Across five years, Gross Profit topped out at $18.1 million in Q3 2022 and bottomed at $298000.0 in Q1 2022.
  • Average Gross Profit over 5 years is $3.9 million, with a median of $1.4 million recorded in 2024.
  • Peak YoY movement for Gross Profit: surged 3131.25% in 2022, then plummeted 91.03% in 2025.
  • A 5-year view of Gross Profit shows it stood at $352000.0 in 2021, then soared by 1853.41% to $6.9 million in 2022, then soared by 144.98% to $16.8 million in 2023, then crashed by 49.5% to $8.5 million in 2024, then tumbled by 91.03% to $763000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $763000.0 in Q4 2025, $2.8 million in Q3 2025, and $1.3 million in Q2 2025.